VEGFA and hepatocellular carcinoma: The multikinase inhibitor sorafenib is one of the few systemic treatment options for advanced hepatocellular carcinoma (HCC) and exerts its anti-proliferative and angiogenesis action by blockage of the Rapidly Accelerated Fibrosarcoma (RAF) and vascular endothelial growth factor (VEGF) signaling and promises better survival for patients with advanced hepatocellular carcinoma [1].